

EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions

Paris, France (15 October 2025) – EssilorLuxottica announces the acquisition of Ikerian AG, a health technology company, operating under the RetinAI brand, specializing in AI and data management in eyecare. This move reinforces the Group's med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and pharmaceutical workflows, and deliver actionable AI-driven insights that empower healthcare professionals and enhance patient care.

RetinAI develops advanced tools to collect, process and grade large-scale retinal images and biomarker datasets. Its FDA cleared 510(k) and CE-marked flagship platform, RetinAI Discovery, applies AI models to support diagnosis and monitoring of disease progression – including age-related macular degeneration (AMD), glaucoma and diabetic retinopathy – enabling more accurate and timely decisions in managing eye diseases. At the same time, RetinAI partners with pharmaceutical companies and research organizations that leverage proprietary real-world evidence to accelerate clinical studies and drug development.

"In the past year alone, we've made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey. RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation and surgical excellence. Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring. We are ushering in a new era of healthcare, and it will be transformative for patients everywhere", commented Francesco Milleri, Chairman and CEO at EssilorLuxottica.

"Joining EssilorLuxottica marks a defining moment in our journey. This acquisition opens an exciting new chapter for our team and technology. From the start, we've believed in the power of data and AI to transform patient care. With EssilorLuxottica's global reach and deep commitment to innovation, we can now bring that vision to life at an entirely new scale and level of positive impact. Together, we'll shape how technology drives better healthcare, sharper vision, and improved outcomes for patients," said Carlos Ciller, PhD Chairman and CEO of RetinAI / Ikerian AG.

Contacts

Giorgio Iannella
Head of Investor Relations
ir@essilorluxottica.com

Marco Catalani
Head of Corporate Communications
media@essilorluxottica.com

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of advanced vision care products, eyewear and med-tech solutions. Its Mission is to help people around the world to see more and be more by addressing their evolving vision needs, personal style aspirations and desire to feel more connected to the world around them. EssilorLuxottica is home to the most innovative lens technologies, including Varilux, Stellest and Transitions, iconic brands such as Ray-Ban, Oakley and Supreme, the most desired luxury licensed brands and world-class retailers including Sunglass Hut, LensCrafters, Vision Express and Apollo. Backed by robust R&D investments, distinctive capabilities and a top-quality asset portfolio, the Company drives innovation across categories, from cutting-edge medical instruments and solutions for eye health to category-defining smart glasses, all of which push the boundaries of the industry and reimagine the eyes as a gateway to new possibilities. With over 200,000 employees across 150 countries, 600 operations facilities, serving 300,000 eye care professionals and operating 18,000 stores, the Group generated consolidated revenue of Euro 26.5 billion in 2024. Its OneSight EssilorLuxottica Foundation has given access to sustainable vision care to nearly 1 billion people in underserved communities. EssilorLuxottica trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP. www.essilorluxottica.com

Contacts

About Ikerian AG and RetinAI Inc. U.S.

Investor Relations

media@retinai.com

Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc. ('Ikerian', 'RetinAI' and, together, 'the company'), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. A commercial stage company with growing sales from RetinAI Discovery®, RetinAI has established collaborations and partnerships with leading ophthalmology clinical networks and pharmaceutical companies. About Ikerian AG www.ikerian.com and RetinAI Inc. US www.retinai.com